Association of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Cohort

Autor: Christina C. Dahm, Inger T. Gram, Elom K. Aglago, Eva Ardanaz, Bas Bueno-de-Mesquita, Krasimira Aleksandrova, David J. Hughes, Joseph A. Rothwell, Anja Olsen, Renée Turzanski-Fortner, Elisabete Weiderpass, Mazda Jenab, Valeria Pala, R. Tumino, Marie-Christine Boutron-Ruault, Thyra Löwenmark, Semi Zouiouich, María Dolores Chirlaque, Rudolf Kaaks, Gianluca Severi, Carlotta Sacerdote, Jill Werner, Carla H. van Gils, Marko Lukic, Salvatore Panico, Richard Palmquist, Heinz Freisling, Ruth C. Travis, Matthias B. Schulze, Núria Sala, Tim Waterboer, María José Pérez, Amanda J. Cross, Alicia K Heath, Julia Butt, Veronika Fedirko, Domenico Palli, Anne Tjønneland
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Male
Colorectal cancer
serology
RC799-869
medicine.disease_cause
Serology
Bacteroides fragilis
0302 clinical medicine
Odds Ratio
Prospective Studies
Escherichia coli Infections
Gastroenterology
food and beverages
Metalloendopeptidases
Diseases of the digestive system. Gastroenterology
Middle Aged
Bacteroides Infections
Antibodies
Bacterial

Europe
Prospective
Infectious Diseases
bacteroides fragilis
Cohort
030211 gastroenterology & hepatology
Female
Colorectal Neoplasms
0605 Microbiology
Research Article
Research Paper
Microbiology (medical)
Adult
Colon
Bacterial Toxins
Gastroenterology and Hepatology
Biology
Microbiology
03 medical and health sciences
Càncer colorectal
medicine
Gastroenterologi
Escherichia coli
Biomarkers
Tumor

Humans
VDP::Medisinske Fag: 700
Bacteroides fragilis toxin
Aged
Antigens
Bacterial

Bacils
prospective
medicine.disease
biology.organism_classification
VDP::Medical disciplines: 700
Bacillus (Bacteria)
030104 developmental biology
Antibody response
Escheríchia coli
Zdroj: Gut Microbes
article-version (VoR) Version of Record
Butt, J, Jenab, M, Werner, J, Fedirko, V, Weiderpass, E, Dahm, C C, Tjønneland, A, Olsen, A, Boutron-Ruault, M-C, Rothwell, J A, Severi, G, Kaaks, R, Turzanski-Fortner, R, Aleksandrova, K, Schulze, M, Palli, D, Pala, V, Panico, S, Tumino, R, Sacerdote, C, Bueno-de-Mesquita, B, Van Gils, C H, Gram, I T, Lukic, M, Sala, N, Sánchez Pérez, M J, Ardanaz, E, Chirlaque, M-D, Palmquist, R, Löwenmark, T, Travis, R C, Heath, A, Cross, A J, Freisling, H, Zouiouich, S, Aglago, E, Waterboer, T & Hughes, D J 2021, ' Association of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Cohort ', Gut Microbes, vol. 13, no. 1, pp. 1-14 . https://doi.org/10.1080/19490976.2021.1903825
Gut Microbes, Vol 13, Iss 1 (2021)
Dipòsit Digital de la UB
Universidad de Barcelona
Digibug. Repositorio Institucional de la Universidad de Granada
instname
Butt, J, Jenab, M, Werner, J, Fedirko, V, Weiderpass, E, Dahm, C C, Tjønneland, A, Olsen, A, Boutron-Ruault, M C, Rothwell, J A, Severi, G, Kaaks, R, Turzanski-Fortner, R, Aleksandrova, K, Schulze, M, Palli, D, Pala, V, Panico, S, Tumino, R, Sacerdote, C, Bueno-de-Mesquita, B, Van Gils, C H, Gram, I T, Lukic, M, Sala, N, Sánchez Pérez, M J, Ardanaz, E, Chirlaque, M D, Palmquist, R, Löwenmark, T, Travis, R C, Heath, A, Cross, A J, Freisling, H, Zouiouich, S, Aglago, E, Waterboer, T & Hughes, D J 2021, ' Association of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Cohort ', Gut Microbes, vol. 13, no. 1 . https://doi.org/10.1080/19490976.2021.1903825
ISSN: 1949-0984
1949-0976
Popis: The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); the Sicilian Government, AIRE ONLUS Ragusa, AVIS Ragusa, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (the Netherlands); Nordic Centre of Excellence programme on Food, Nutrition and Health. (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia, Navarra, and the Catalan Institute of Oncology (Barcelona), Spain; Swedish Cancer Society, Swedish Scientific Council, and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (C864/A14136 to EPIC-Norfolk; C8221/A19170, C570/A16491 and C8221/ A290170 to EPIC-Oxford), Medical Research Council (MR/ N003284/1 and MC-UU_12015/1 to EPIC-Norfolk, MR/ M012190/1 to EPIC-Oxford (UK). The funding sources had no influence on the design of the study; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication.Support for this study was also provided by the COST Action CA17118 supported by COST (European Cooperation in Science and Technology, www.cost.eu) to DJH.
Experimental evidence has implicated genotoxic Escherichia coli (E. coli) and enterotoxigenic Bacteroides fragilis (ETBF) in the development of colorectal cancer (CRC). However, evidence from epidemiological studies is sparse. We therefore assessed the association of serological markers of E. coli and ETBF exposure with odds of developing CRC in the European Prospective Investigation into Nutrition and Cancer (EPIC) study. Serum samples of incident CRC cases and matched controls (n = 442 pairs) were analyzed for immunoglobulin (Ig) A and G antibody responses to seven E. coli proteins and two isoforms of the ETBF toxin via multiplex serology. Multivariable-adjusted conditional logistic regression analyses were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association of sero-positivity to E. coli and ETBF with CRC. The IgA-positivity of any of the tested E. coli antigens was associated with higher odds of developing CRC (OR: 1.42; 95% CI: 1.05–1.91). Dual-positivity for both IgA and IgG to E. coli and ETBF was associated with >1.7-fold higher odds of developing CRC, with a significant association only for IgG (OR: 1.75; 95% CI: 1.04, 2.94). This association was more pronounced when restricted to the proximal colon cancers (OR: 2.62; 95% CI: 1.09, 6.29) compared to those of the distal colon (OR: 1.24; 95% CI: 0.51, 3.00) (pheterogeneity = 0.095). Sero-positivity to E. coli and ETBF was associated with CRC development, suggesting that co-infection of these bacterial species may contribute to colorectal carcinogenesis. These findings warrant further exploration in larger prospective studies and within different population groups.
European Commission (DG-SANCO)
International Agency for Research on Cancer
Danish Cancer Society (Denmark)
Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France)
Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany)
Hellenic Health Foundation (Greece)
Sicilian Government, AIRE ONLUS Ragusa, AVIS Ragusa, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, and National Research Council (Italy)
Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (the Netherlands)
Nordic Centre of Excellence programme on Food, Nutrition and Health. (Norway)
Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia, Navarra, and the Catalan Institute of Oncology (Barcelona), Spain
Swedish Cancer Society, Swedish Scientific Council, and County Councils of Skåne and Västerbotten (Sweden)
Cancer Research UK (C864/A14136 to EPIC-Norfolk; C8221/A19170, C570/A16491 and C8221/ A290170 to EPIC-Oxford), Medical Research Council (MR/ N003284/1 and MC-UU_12015/1 to EPIC-Norfolk, MR/ M012190/1 to EPIC-Oxford (UK)
COST Action CA17118 supported by COST (European Cooperation in Science and Technology)
Databáze: OpenAIRE